Following a successful preclinical program completion demonstrating the efficacy and safety of its lead compound, Ir‑CPI, Bioxodes SA has completed a EUR 7.65 million capital increase. It was carried out among the current shareholders as well as new investors. A repayable advance of EUR 2.65 million was granted by the Walloon Region which has been actively supportive since the creation of the company. With this capital increase, Bioxodes SA wishes to demonstrate the safety of Ir-CPI in humans (Phase I) but also to obtain first proofs of efficacy in patients.